Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps
Source: SeekingAlpha
2025-09-24 08:05:58 ET
More on Acadia Pharma, Soleno Therapeutics
- Soleno Therapeutics: Patient Death Unrelated To Vykat, But Safety Concerns May Undermine Launch
- ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
- Soleno Therapeutics, Inc. (SLNO) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
- Soleno drops on death of patient treated with Vykat XR
- Acadia raises 2025 NUPLAZID guidance to $665M–$690M as DAYBUE accelerates community uptake
Read the full article on Seeking Alpha
For further details see:
Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps
Soleno Therapeutics Inc.
NASDAQ: SLNO
SLNO Trading
0.82% G/L:
$33.795 Last:
92,939 Volume:
$33.87 Open:
SLNO Latest News
March 13, 2026 06:28:00 pm
Notice to Long-Term Investors of Soleno Therapeutics, Inc. (SLNO): Grabar Law Office Investigates Claims on Your Behalf
March 13, 2026 02:45:00 pm
Deadline Approaching: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
SLNO Stock Data
$2,184,386,717
45,438,681
1.25%
73
N/A
Biotechnology & Life Sciences
Healthcare
US
Redwood City
